J H Lin

发表

The integration of medicinal chemistry, drug metabolism, and pharmaceutical research and development in drug discovery and development. The story of Crixivan, an HIV protease inhibitor.

J. Vacca, J. Lin, J P Vacca, 1998, Pharmaceutical biotechnology.

Blood-brain barrier permeability and in vivo activity of partial agonists of benzodiazepine receptor: a study of L-663,581 and its metabolites in rats.

J H Lin, I W Chen, T H Lin, 1994, The Journal of pharmacology and experimental therapeutics.

Is the role of the small intestine in first-pass metabolism overemphasized?

T. Baillie, J. Lin, M. Chiba, 1999, Pharmacological reviews.

Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile.

R R Miller, B H Arison, S K Balani, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.

E A Emini, L. Kuo, P. Darke, 2000, Journal of medicinal chemistry.

Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.

S K Balani, J. Lin, M. Chiba, 1996, Drug metabolism and disposition: the biological fate of chemicals.

In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4.

S K Balani, T. Baillie, J. Lin, 1996, Chemical research in toxicology.

beta-Oxidation of simvastatin in mouse liver preparations.

J H Lin, T Prueksaritanont, B Ma, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Role of pharmacokinetics and metabolism in drug discovery and development.

A. Y. Lu, J. Lin, A Y Lu, 1997, Pharmacological reviews.

L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor.

J. Vacca, J. Shafer, Z. Chen, 1998, Bioorganic & medicinal chemistry letters.

Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support.

S. Brady, J. Vacca, S. Gardell, 1998, Journal of medicinal chemistry.

Sense and nonsense in the prediction of drug-drug interactions.

J. Lin, J H Lin, 2000, Current drug metabolism.

Bisphosphonates: a review of their pharmacokinetic properties.

J. Lin, J H Lin, 1996, Bone.

Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation.

J. Lin, E. Blasko, C. Glaser, 1992, The Journal of clinical investigation.

In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.

J. Hochman, J. Lin, T. Ohe, 2001, The Journal of pharmacology and experimental therapeutics.